These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23919274)

  • 1. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
    van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
    Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.
    van Heumen BW; Roelofs HM; te Morsche RH; Nagengast FM; Peters WH
    Orphanet J Rare Dis; 2013 Nov; 8():181. PubMed ID: 24245549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
    Phillips RK; Wallace MH; Lynch PM; Hawk E; Gordon GB; Saunders BP; Wakabayashi N; Shen Y; Zimmerman S; Godio L; Rodrigues-Bigas M; Su LK; Sherman J; Kelloff G; Levin B; Steinbach G;
    Gut; 2002 Jun; 50(6):857-60. PubMed ID: 12010890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
    van Heumen BW; Roelofs HM; Te Morsche RH; Marian B; Nagengast FM; Peters WH
    Exp Cell Res; 2012 Apr; 318(7):819-27. PubMed ID: 22366264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
    Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
    JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ursodesoxycholic acid on duodenal adenomas in familial adenomatous polyposis: a prospective randomized placebo-control trial.
    Parc Y; Desaint B; Fléjou JF; Lefèvre JH; Serfaty L; Vienne A; Kotti S; Simon T; Tiret E
    Colorectal Dis; 2012 Jul; 14(7):854-60. PubMed ID: 21899713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
    N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
    Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
    Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.
    Huang K; Gutierrez LP; Bülow S; Gallinger S; Castells A; Eagle CJ; Church JM
    Fam Cancer; 2011 Jun; 10(2):303-8. PubMed ID: 21359561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib in a 12-year-old boy with familial adenomatous polyposis.
    Pérez-Segura P; Bodas A; Sereno M; Martínez-Amores B; Olivera H; Díaz S; López-Asenjo JA; Puente J; Maluenda C; Díaz-Rubio E
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):230-2. PubMed ID: 20197018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
    Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
    Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis.
    Park JJ; Kim BC; Hong SP; Seo Y; Lee HS; Park YS; Na SY; Park SC; Park J; Kim JH; Moon CM; Huh KC; Park SJ; Cheon JH; Kim WH; Kim TI
    Cancer Prev Res (Phila); 2021 May; 14(5):563-572. PubMed ID: 33509804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
    Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
    BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
    Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.